Compound A1LXN

InChi:

InChI=1S/C6H7N5O/c1-2-8-3-4(9-2)10-6(7)11-5(3)12/h1H3,(H4,7,8,9,10,11,12)

SMARTS:

[#6]-[#6]1:[#7]:[#6]2:[#7]:[#6](-[#7]):[#7]:[#6](=[#8]):[#6]:2:[#7]:1

Lipinski's RO5	Veber	Pfizer's 3/75

PDB code	Deposition date	Reference publication
8xzp	Jan. 21, 2024	Li Chunyan, Xu Xiaochen, Geng Zhi, Zheng Luqian, Song Qianqian, Shen Xin, Wu Jingjing, zhao Jin, Li Hongcheng, He Mengqi, Tai Xiaoqing, Zhang Long, Ma Jinbiao, Dong Yuhui, Ren Aiming. 2024. Structure-based characterization and compound identification of the wild-type THF class-II riboswitch Nucleic Acids Research
9v50	May 24, 2025	Li Hongcheng, Shen Xin, Xu Xiaochen, Tai Xiaoqing, He Mengqi, Zhang Jinzhu, Ren Aiming. 2025. Ligand specificity and adaptability revealed by the first Guanine-II riboswitch tertiary structure Nucleic Acids Research

Descriptor	Lipinski's RO5	Veber	Pfizer's 3/75
MW	≤ 500 g/mol	-	-
AlogP	≤ 5	-	≤ 3
HBA	≤ 10	-	-
HBD	≤ 5	-	-
(HBA + HBD)	-	≤ 12	-
TPSA	-	≤ 140 Å²	≥ 75 Å²
RB	-	≤ 10	-

HARIBOSS